292 related articles for article (PubMed ID: 9835514)
1. Bacteriological efficacies of three macrolides compared with those of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Berry V; Thorburn CE; Knott SJ; Woodnutt G
Antimicrob Agents Chemother; 1998 Dec; 42(12):3193-9. PubMed ID: 9835514
[TBL] [Abstract][Full Text] [Related]
2. Comparative bacteriological efficacy of pharmacokinetically enhanced amoxicillin-clavulanate against Streptococcus pneumoniae with elevated amoxicillin MICs and Haemophilus influenzae.
Berry V; Hoover J; Singley C; Woodnutt G
Antimicrob Agents Chemother; 2005 Mar; 49(3):908-15. PubMed ID: 15728883
[TBL] [Abstract][Full Text] [Related]
3. In vitro selection of resistance in Haemophilus influenzae by amoxicillin-clavulanate, cefpodoxime, cefprozil, azithromycin, and clarithromycin.
Clark C; Bozdogan B; Peric M; Dewasse B; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 2002 Sep; 46(9):2956-62. PubMed ID: 12183253
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial effects of amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae strains for which MICs are high, in an in vitro pharmacokinetic model.
MacGowan AP; Noel AR; Rogers CA; Bowker KE
Antimicrob Agents Chemother; 2004 Jul; 48(7):2599-603. PubMed ID: 15215115
[TBL] [Abstract][Full Text] [Related]
5. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae.
Woodnutt G; Berry V
Antimicrob Agents Chemother; 1999 Jan; 43(1):29-34. PubMed ID: 9869561
[TBL] [Abstract][Full Text] [Related]
6. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
Neuhauser MM; Prause JL; Danziger LH; Pendland SL
Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
[TBL] [Abstract][Full Text] [Related]
7. Large dosage amoxicillin/clavulanate, compared with azithromycin, for the treatment of bacterial acute otitis media in children.
Hoberman A; Dagan R; Leibovitz E; Rosenblut A; Johnson CE; Huff A; Bandekar R; Wynne B
Pediatr Infect Dis J; 2005 Jun; 24(6):525-32. PubMed ID: 15933563
[TBL] [Abstract][Full Text] [Related]
8. Incidence of antibiotic-resistant Streptococcus pneumoniae and beta-lactamase-positive Haemophilus influenzae in clinical isolates from patients with otitis media.
McLinn S; Williams D
Pediatr Infect Dis J; 1996 Sep; 15(9 Suppl):S3-9. PubMed ID: 8878239
[TBL] [Abstract][Full Text] [Related]
9. The Viriato Study: update of antimicrobial susceptibility data of bacterial pathogens from community-acquired respiratory tract infections in Portugal in 2003 and 2004.
Melo-Cristino J; Santos L; Ramirez M;
Rev Port Pneumol; 2006; 12(1):9-30. PubMed ID: 16572254
[TBL] [Abstract][Full Text] [Related]
10. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
Thornsberry C; Ogilvie P; Kahn J; Mauriz Y
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):249-57. PubMed ID: 9458982
[TBL] [Abstract][Full Text] [Related]
11. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia.
Torumkuney D; Mayanskiy N; Edelstein M; Sidorenko S; Kozhevin R; Morrissey I
J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v14-v21. PubMed ID: 29659881
[TBL] [Abstract][Full Text] [Related]
12. Microbiologic activity of the newer macrolide antibiotics.
McCracken GH
Pediatr Infect Dis J; 1997 Apr; 16(4):432-7. PubMed ID: 9109155
[TBL] [Abstract][Full Text] [Related]
13. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Greece.
Torumkuney D; Papaparaskevas J; Morrissey I
J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v36-v42. PubMed ID: 29659884
[TBL] [Abstract][Full Text] [Related]
14. Human serum activity of telithromycin, azithromycin and amoxicillin/clavulanate against common aerobic and anaerobic respiratory pathogens.
Stein GE; Schooley S; Tyrrell KL; Citron DM; Goldstein EJ
Int J Antimicrob Agents; 2007 Jan; 29(1):39-43. PubMed ID: 17189093
[TBL] [Abstract][Full Text] [Related]
15. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of the new ketolide HMR 3004 compared to an azalide and macrolides against Streptococcus pneumoniae and Haemophilus influenzae.
Barry AL; Fuchs PC; Brown SD
Eur J Clin Microbiol Infect Dis; 1997 Oct; 16(10):767-9. PubMed ID: 9405952
[TBL] [Abstract][Full Text] [Related]
17. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
18. Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides.
Drago L; De Vecchi E; Nicola L; Colombo A; Gismondo MR
J Antimicrob Chemother; 2004 Aug; 54(2):542-5. PubMed ID: 15215227
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.
Doern GV; Brueggemann AB; Pierce G; Holley HP; Rauch A
Antimicrob Agents Chemother; 1997 Feb; 41(2):292-7. PubMed ID: 9021182
[TBL] [Abstract][Full Text] [Related]
20. Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
Hoogkamp-Korstanje JA; Dirks-Go SI; Kabel P; Manson WL; Stobberingh EE; Vreede RW; Davies BI
J Antimicrob Chemother; 1997 Mar; 39(3):411-4. PubMed ID: 9096192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
